An Evaluation of the Systemic Impact and Clinical Efficacy of Sequential Vincristine Sulfate Versus Doxorubicin in the Post-operative Management of Canine Mammary Tumours (CMT)

The present study was conducted to evaluate the systemic impact and clinical efficacy of sequential vincristine sulfate compared to doxorubicin in the post-operative management of Canine Mammary Tumours (CMT) on 18 clinical cases of mammary tumour of various breed, irrespective of their age, sex and divided into three groups consisting of 6 animals in each. Group Surgery was treated with surgical removal of tumouronly while animals of Group Surg Dox and Group Surg Vin were treated with surgical excision followed by administration of Doxorubicin (30mg/m2) BSA and Vincristine sulfate (0.025 mg/kg) intravenously along with DNS at 7th and 14th post-operative days respectively. The haemato-biochemical parameters and wound evaluation were done at different time intervals. Systemic impact on haematological and biochemical parameters were briefly altered and chemotherapeutic medications does not induce any adverse reactions or detrimental effects on vital organs, but these changes remained within the normal physiological range. Doxorubicin and vincristine sulfate therapy showed minimum to no reoccurrence of tumour with few adverse reactions such as inappetance, vomition, anaemia and alopecia. However, these conditions were managed by supportive therapy. Therefore, it could be concluded that sequential vincristine therapy is best for the post-operative management of canine mammary tumours as it effectively regressed the tumour without relapse.